METASTRON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METASTRON is an injectable NDA-approved pharmaceutical product sponsored by Q BioMed with a regulatory approval dating to June 1993. The specific mechanism of action, pharmacologic class, and clinical indications are not currently documented in available data. The product is administered via injection and represents a mature therapeutic asset.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100); commercial team sizing likely reflects mature product consolidation and focus on market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on METASTRON offers limited near-term career expansion due to zero current linked job openings and approaching loss of exclusivity. Career trajectory is best suited for professionals focused on defensive market strategies, cost optimization, and legacy product portfolio management.
Brand ManagerField Sales Representative
Worked on METASTRON at Q BioMed? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.